BDB-001, was under investigation in multiple clinical trials to evaluate its safety, tolerability, and efficacy across various conditions. In NCT05075304 and NCT04449588, BDB-001 was studied in mild to severe COVID-19 patients. It was also explored for solid tumors in NCT03486301, NCT04196530, and NCT04819373, either as monotherapy or combined with Pembrolizumab or Atezolizumab, and in NCT03915678 with Atezolizumab and immunogenic radiotherapy. Additionally, NCT05197842 investigated its use in ANCA-associated vasculitis, and NCT05103423 and NCT05093855 focused on moderate to severe Hidradenitis Suppurativa.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.